Aim: Chemerin is a novel adipokine that has been suggested to play an important role in the pathogenesis of themetabolic syndrome. The aim of our study was to evaluate serum chemerin as a marker of the metabolic syndromeand to assess its predictive accuracy in a Caucasian population. Methods: The study was designed as a cross-sectional study. Anthropometric measurements and serum analyseswere done for Body Mass Index, waist circumference, chemerin, insulin, triacylglycerides, total cholesterol, HDLcholesterol,LDL-cholesterol, uric acid, and glucose in 55 non-obese healthy subjects and 181 subjects at risk for themetabolic syndrome. ROC curves were determined and the Chi-squared test was used to analyse the data. Results: Compared with healthy controls, subjects with suspected metabolic syndrome had signifi cantly higherchemerin serum levels (medians: 266.0 vs.192.5 µg/l; P < 0.01). After further chemerin adjustment, the diff erencebetween the subgroups persisted. Chemerin serum levels correlated with age (r = 0.23), serum glucose (r = 0.23),HDL-cholesterol (r = –0.19), triacylglycerides (r = 0.22), systolic and diastolic blood pressure (r = 0.40; r = 0.24) andthe number of metabolic syndrome risk factors (r = 0.47). At a serum chemerin cut-off level of 240 µg/l, the presenceof the metabolic syndrome was diagnosed with 75 % sensitivity and 67 % specifi city.Conclusion: In conclusion, serum chemerin levels are associated with the characteristics of the metabolic syndromeand could be an independent marker of this disorder in a Caucasian population.

Department of Laboratory Medicine and Internal Department Sternberk Hospital Sternberk

Citace poskytuje Crossref.org

Lit.: 6